清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection Fraction

医学 心力衰竭 射血分数 内科学 射血分数保留的心力衰竭 倾向得分匹配 心脏病学 队列
作者
Lars H. Lund,Lina Benson,Ulf Dahlström,Magnus Edner
出处
期刊:JAMA [American Medical Association]
卷期号:308 (20): 2108-2108 被引量:166
标识
DOI:10.1001/jama.2012.14785
摘要

Context

Heart failure with preserved ejection fraction (HFPEF) may be as common and as lethal as heart failure with reduced ejection fraction (HFREF). Three randomized trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ie, renin-angiotensin system [RAS] antagonists) did not reach primary end points but may have had selection bias or been underpowered.

Objective

To test the hypothesis that use of RAS antagonists is associated with reduced all-cause mortality in an unselected population with HFPEF.

Design, Setting, and Patients

Prospective study using the Swedish Heart Failure Registry of 41 791 unique patients registered from 64 hospitals and 84 outpatient clinics between 2000 and 2011. Of these, 16 216 patients with HFPEF (ejection fraction ≥40%; mean [SD] age, 75 [11] years; 46% women) were either treated (n = 12 543) or not treated (n = 3673) with RAS antagonists. Propensity scores for RAS antagonist use were derived from 43 variables. The association between use of RAS antagonists and all-cause mortality was assessed in a cohort matched 1:1 based on age and propensity score and in the overall cohort with adjustment for propensity score as a continuous covariate. To assess consistency, separate age and propensity score–matched analyses were performed according to RAS antagonist dose in patients with HFPEF and in 20 111 patients with HFREF (ejection fraction <40%) in the same registry.

Main Outcome Measure

All-cause mortality.

Results

In the matched HFPEF cohort, 1-year survival was 77% (95% CI, 75%-78%) for treated patients vs 72% (95% CI, 70%-73%) for untreated patients, with a hazard ratio (HR) of 0.91 (95% CI, 0.85-0.98; P = .008). In the overall HFPEF cohort, crude 1-year survival was 86% (95% CI, 86%-87%) for treated patients vs 69% (95% CI, 68%-71%) for untreated patients, with a propensity score–adjusted HR of 0.90 (95% CI, 0.85-0.96; P = .001). In the HFPEF dose analysis, the HR was 0.85 (95% CI, 0.78-0.83) for 50% or greater of target dose vs no treatment (P < .001) and 0.94 (95% CI, 0.87-1.02) for less than 50% of target dose vs no treatment (P = .14). In the age and propensity score–matched HFREF analysis, the HR was 0.80 (95% CI, 0.74-0.86; P < .001).

Conclusion

Among patients with heart failure and preserved ejection fraction, the use of RAS antagonists was associated with lower all-cause mortality.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
羞涩的傲菡完成签到,获得积分10
2秒前
武雨寒发布了新的文献求助10
4秒前
兴奋乞完成签到,获得积分10
19秒前
零度空间完成签到,获得积分10
20秒前
痴情的不惜完成签到,获得积分10
30秒前
32秒前
整齐念薇完成签到,获得积分10
32秒前
武雨寒发布了新的文献求助10
36秒前
50秒前
诸葛平卉完成签到 ,获得积分10
50秒前
星辰大海的应助被psm采纳,获得10
54秒前
54秒前
飞天大南瓜完成签到,获得积分10
56秒前
Gilgardea发布了新的文献求助10
59秒前
车车完成签到 ,获得积分10
1分钟前
精明开山完成签到,获得积分10
1分钟前
1分钟前
鲤鱼遥完成签到,获得积分10
1分钟前
cat发布了新的文献求助10
1分钟前
AG完成签到,获得积分10
1分钟前
田田完成签到 ,获得积分10
1分钟前
1分钟前
等待凡英完成签到,获得积分10
1分钟前
陈荆洲完成签到,获得积分10
1分钟前
高高的玉兰完成签到,获得积分10
1分钟前
1分钟前
小二郎的应助被cat采纳,获得10
1分钟前
科研通AI6.2的应助被pitinmoon采纳,获得10
1分钟前
漂亮秋荷完成签到,获得积分10
1分钟前
腼腆的雪珊完成签到,获得积分10
1分钟前
淡淡傲柔完成签到,获得积分10
2分钟前
hyk完成签到 ,获得积分10
2分钟前
Orange的应助被Gilgardea采纳,获得10
2分钟前
安详的老五完成签到,获得积分10
2分钟前
欢呼的听枫完成签到,获得积分10
2分钟前
顺利大有完成签到,获得积分10
2分钟前
满意的伊完成签到,获得积分10
3分钟前
年轻的幼菱完成签到,获得积分10
3分钟前
诺一44发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166413
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750478
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473835